Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

NCT07294261 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Local Advanced or Metastatic NSCLC

Interventions

DRUG: Garsorasib, Benmelstobart, Anlotinib
DRUG: Benmelstobart, Anlotinib
DRUG: Garsorasib, Cetuximab Beta Injection

Sponsor

Sun Yat-sen University

Collaborators

[object Object]